LONDON (Alliance News) - Electrical Geodesics Inc Thursday said it is to start the first clinical studies for its GTEN 100 transcranial electrical neuromodulation system in early 2015.
The initial study is set to assess the feasibility of using GTEN 100 in temporary seizure suppression in patients suffering from drug-resistant epilepsy. The goal of the study will be to demonstrate a reduction in the exitability of the cortex at the site of a seizure onset.
A number of leading epilepsy centres are participating in the study, including the University of Washington Harborview Hospital, Seattle, Harvard Medical School Beth Israel Deaconess Hospital, Boston, and Stanford University Hospital, Palo Alto and Huashan Hospital, Shanghai.
"We are highly encouraged by the support we have received from these key international epilepsy centres," Electrical Geodesics Chairman and Chief Executive Don Tucker said in a statement.
"We plan to investigate the use of our neuromodulation technology in a number of other important indications, such as depression, building on the results of this first feasibility trial," Tucker added.
The company's shares were down 1.8% at 138.00 pence early Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
